COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The global pneumococcal vaccine market is expected to grow at a CAGR of 6.17% to reach a total market size of US$10.436 billion by 2023, increasing from US$7.287 billion in 2017. Rising incidence of pneumococcal diseases like pneumonia, meningitis, febrile bacteraemia, otitis media, sinusitis, bronchitis and others is driving the demand for pneumococcal vaccines. According to WHO, pneumococcal vaccine had been introduced in 134 countries by 2016 end and estimated global coverage was about 42%. Growing awareness regarding the importance of vaccination and increasing spending by the governments towards public health is fuelling the development of pneumococcal vaccines in the developing countries. Major market players in the global pneumococcal vaccine market are Pfizer, Sanofi, GSK, Merck, AstraZeneca and Baxter International.
By Type
On the basis of type, pneumococcal vaccine market is segmented as conjugate vaccines and polysaccharide vaccines. Out of these two, conjugate vaccines are more robust as compared to the polysaccharide ones and hence have a significant market share.
By Geography
In terms of geography, global pneumococcal vaccine segmentation includes North America, South America, Europe, Middle East and Africa, and Asia-Pacific. Rising awareness programmes regarding the proper vaccination is driving the market growth in developing and underdeveloped countries.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical regions. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global pneumococcal vaccine value chain. Last step involves complete market engineering which includes analyzing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Pfizer, Sanofi Pasteur MSD, GSK, and Merck among others.